← Back to Search

APOL1 Genetic Testing for Kidney Disease

N/A
Recruiting
Led By Elisa J Gordon
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cognitively intact individuals
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately day 60
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how well a chatbot-based program works in informing African American adults about their risk for kidney disease if they donate a kidney.

Who is the study for?
This trial is for cognitively intact, English-speaking adults of African descent, including a wide range of nationalities like African American/Black, Jamaican, and others who are considering becoming living kidney donors. It's not for those without African ancestry or pregnant women.
What is being tested?
The study tests a culturally adapted APOL1 genetic testing program with components like genetic counseling and EHR integration. It uses the 'Gia' chatbot to help potential donors understand their risks and make informed decisions about donation.
What are the potential side effects?
Since this trial involves genetic testing and counseling rather than medication or invasive procedures, traditional side effects are not applicable. However, participants may experience emotional or psychological impacts from learning about their genetic risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am mentally sharp and can make decisions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately day 60
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately day 60 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Decisional Conflict Scale (DCS)
Secondary study objectives
Preparation for Decision Making Scale (PDMS) Scores range from: Higher scores reflect greater preparation for decision making (a better outcome)
Satisfaction with the Informed Consent Process
Willingness to Donate Scores range from: 0 to 10. Higher scores reflect greater willingness to donate.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention ArmExperimental Treatment3 Interventions
APOL1 testing program
Group II: Control ArmActive Control1 Intervention
No intervention will be administered. Usual care will be administered.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,647 Previous Clinical Trials
958,262 Total Patients Enrolled
Georgetown UniversityOTHER
348 Previous Clinical Trials
136,912 Total Patients Enrolled
Elisa J GordonPrincipal InvestigatorNorthwestern University

Media Library

APOL1 genetic testing Clinical Trial Eligibility Overview. Trial Name: NCT04910867 — N/A
Kidney Transplant Research Study Groups: Control Arm, Intervention Arm
Kidney Transplant Clinical Trial 2023: APOL1 genetic testing Highlights & Side Effects. Trial Name: NCT04910867 — N/A
APOL1 genetic testing 2023 Treatment Timeline for Medical Study. Trial Name: NCT04910867 — N/A
~45 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top